Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine (NQ: EDIT )

2.660 -0.110 (-3.97%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Can This Experimental Gene Therapy Be Enough to Lift Editas Medicine in the Future?
EDIT-301 had positive clinical results in treating sickle cell disease, but the potential payoff is still years in the future. 
Via The Motley Fool
2 Reasons to Sell Editas Medicine Stock and 1 Reason to Buy It
Editas Medicine is a high-risk stock with the potential of a big reward. 
Via The Motley Fool
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. 
Via InvestorPlace
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
Thinking of Buying Biotech Stocks? Do These 3 Things First
It's better to plan ahead than to get caught by surprise. 
Via The Motley Fool
Editas Medicine Earnings Preview
Via Benzinga
Top CRISPR Stocks
CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses. 
Via Talk Markets
Why Editas Medicine Stock Charged Higher in January
The genome-editing company's shares spiked following a definitive agreement with Shoreline Biosciences last month. 
Via The Motley Fool
Expert Ratings for Editas Medicine
Via Benzinga
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
These 2 Biotech Stocks Could Soar in the Next Bull Market
They're both at the cutting edge of gene-editing technology. 
Via The Motley Fool
Is Exact Sciences or Editas Medicine the Better Growth Stock to Own in 2023?
Which of these rebounding biotech stocks is the better buy right now? 
Via The Motley Fool
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
Why Shares of Editas Medicine Jumped This Week
It's been a seesaw month for the clinical-stage gene-editing biotech. 
Via The Motley Fool
Shoreline Biosciences Acquires Editas' iNK Cell Franchise, Related Gene Editing Technologies
Via Benzinga
3 No-Brainer Stocks to Buy Right Now for Less Than $25
All three healthcare stocks are showing solid long-term potential. 
Via The Motley Fool
Why Editas Medicine's Shares Jumped This Week
The gene-editing biotech's shares have had a strong two-week run. 
Via The Motley Fool
Is Editas Medicine Stock a Buy Now?
Layoffs and a thin clinical-stage pipeline aren't very encouraging. 
Via The Motley Fool
3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later
CRISPR stocks are heating back up after a difficult 2022. These three names should be at the top of your watchlist. 
Via InvestorPlace
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
Via Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate. 
Via MarketBeat
Topics Workforce
Exposures Layoff Product Safety
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
From Editas Medicine, Inc.
Via GlobeNewswire
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in 10 years. 
Via InvestorPlace
Analyst Expectations for Editas Medicine's Future
Via Benzinga
Why Editas Medicine Stock Is Sliding Today
The gene-editing pioneer announced a big shake-up with its research and development programs. 
Via The Motley Fool
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.